Sativa capitalises on first-mover advantage in UK medicinal cannabis – Proactive Investors UK
What Sativa does
Sativa Group PLC (NEX:SATI) is Britain’s first medicinal cannabis investment vehicle and is now an operating company with two fully trading UK businesses.
Listed on the NEX exchange in March 2018, Sativa was set up to make investments into Canada-based cannabis companies where the drug is now approved for medicinal and recreational use.
Since the legalisation of medicinal cannabis in the UK in late 2018, Sativa has capitalised on its first-mover advantage to become a seed-to-consumer medicinal cannabis and cannabidiol (CBD) wellness business.
It is now focused on the sourcing of raw material, advanced extraction, manufacture, testing, distribution, and research & development of cannabis products.
In October 2019, the company received a controlled drug licence from the UK Home Office, allowing it to produce and supply cannabis at its headquarters in Somerset.
The medicinal cannabis firm said it will immediately begin a research partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.
What Sativa owns
Sativa’s investments include: Canada-based pharmaceutical firm, Veritas Pharma.; Canada pharma-tech business, Rapid Dose Therapeutics, which owns the QuickStrip oral dissolving cannabis strips; and a 60% stake in a joint venture with Germany’s Lexamed GmbH.
Its two operating subsidiaries are testing facility, PhytoVista Laboratories, and George Botanicals, which develops, manufactures and distributes low-Tetrahydrocannabinol (THC) and CBD wellness products.
What the CEO says: Henry Lees-Buckley
“The Goodbody CBD Wellness business completed its three-store pilot phase and is poised to roll-out its franchise model.
“With the George Botanicals brand and PhytoVista laboratories also performing well, prospects look good.”
- Sativa has signed commercial offtake agreements with two suppliers of cannabis oil for the manufacture of CBD products in the UK. These suppliers are Swiss firm, Alponics, and Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda.
- The group is planning to open its first of three Goodbody & Blunt wellness centre in Bath. The centre will sell a range of white label CBD products made by George Botanicals and other suppliers, all of which will be tested by Phytovista.
- Sativa has teamed up with King’s College London to research the impact of CBDs on inflammation and respiratory diseases. Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known CBDs, subject to regulatory approval.
This article originally appeared here in https://www.proactiveinvestors.co.uk/companies/news/217782/sativa-capitalises-on-first-mover-advantage-in-uk-medicinal-cannabis-217782.html